Scarica l'app Stockscreener
33.32
1.52%
0.50
Dopo l'orario di chiusura:
33.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Axogen Inc Borsa (AXGN) Ultime notizie
Prudential Financial Inc. Trims Stake in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq
AxoGen Secures FDA Approval for Avance Nerve Scaffold - The Globe and Mail
HC Wainwright & Co. Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AxoGen Approves New CFO Compensation and Agreement - TipRanks
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Bu - GuruFocus
AXGN Sees Enhanced Price Target by HC Wainwright & Co. Analyst Y - GuruFocus
Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025 - simplywall.st
AxoGen (NASDAQ:AXGN) Shares Gap UpHere's What Happened - MarketBeat
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity - Investing.com Nigeria
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity By Investing.com - Investing.com South Africa
AxoGen, Inc. $AXGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
Will Axogen Inc. stock maintain growth storyWeekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Jefferies Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Bu - GuruFocus
AXGN: Lake Street Maintains "Buy" Rating and Raises Price Target to $40.00 | AXGN Stock News - GuruFocus
Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment - inkl
AxoGen stock price target raised to $36 from $27 at Raymond James - Investing.com Nigeria
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval By Investing.com - Investing.com Nigeria
AxoGen stock price target raised to $36 from $27 at Raymond James By Investing.com - Investing.com India
Axogen's Avance secures FDA approval for nerve repair - BioWorld MedTech
FDA approves Axogen's nerve repair graft - Reuters
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval - Investing.com
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval - Investing.com Nigeria
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval By Investing.com - Investing.com South Africa
Axogen, Inc. (AXGN) Stock: FDA Approval Boosts Avance as a Leading Nerve Repair Solution - parameter.io
Mizuho Begins Coverage on AxoGen (NASDAQ:AXGN) - MarketBeat
FDA Biologic Approval For AVANCE Might Change The Case For Investing In Axogen (AXGN) - simplywall.st
Axogen stock soars after FDA approval for nerve repair product By Investing.com - Investing.com South Africa
Axogen stock soars after FDA approval for nerve repair product - Investing.com
FDA Approves Axogen's (AXGN) Avance for Nerve Repair - GuruFocus
AXGN stock rises pre-market after FDA approves nerve repair graft - MSN
Why Is AXGN Stock Rising Today? - Stocktwits
Axogen (NASDAQ: AXGN) wins FDA Accelerated Approval for Avance nerve graft, eyes Q2 2026 launch - Stock Titan
Axogen, Inc. Announces FDA Approval of Avance® Biologics License - TradingView
Axogen Says FDA Approved Biologics License Application for Avance; Shares Rise Pre-Bell - marketscreener.com
Citizens reiterates Market Outperform rating on AxoGen stock, citing differentiated products - Investing.com
Will Axogen Inc. stock outperform Nasdaq indexDip Buying & Long-Term Capital Growth Strategies - Newser
Axogen gets FDA OK for Avance’s biologics license application (AXGN:NASDAQ) - Seeking Alpha
FDA approves Axogen’s nerve repair scaffold under biologics license By Investing.com - Investing.com South Africa
AxoGen Inc - Reuters
FDA approves Axogen’s nerve repair scaffold under biologics license - Investing.com India
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft-arwx) - The Manila Times
FDA Approves Axogen's AVANCE Nerve Allograft For Peripheral Nerve Repair - Nasdaq
Axogen, Inc. Receives FDA Approval for AVANCE® Biologics License Application to Treat Peripheral Nerve Discontinuities - Quiver Quantitative
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) - GlobeNewswire
FDA approves Axogen’s nerve repair graft - Northland News Radio
Fda: approval for avance was granted to axogen corporation - marketscreener.com
What momentum indicators show for Axogen Inc. stockEarnings Recap Report & Verified Chart Pattern Trade Signals - Newser
AxoGen, Inc. (NASDAQ:AXGN) Q3 2025 Earnings Call Transcript - MSN
FDA approves Axogen's nerve repair graft | Business Information & News | FE - Westlaw Today
AxoGen (NASDAQ:AXGN) Sets New 12-Month HighHere's What Happened - MarketBeat
Axogen (AXGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Mizuho initiates coverage on AxoGen stock with Outperform rating By Investing.com - Investing.com South Africa
Mizuho Initiates Coverage of Axogen (AXGN) with Outperform Recommendation - Nasdaq
3.78%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):